10x Genomics to Report Second Quarter Financial Results on August 11, 2020

NEXT STORY
Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range
PREV STORY
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event

author_avatar
NASDAQ Market News

Surface Oncology to Present Clinical Updates for SRF388 and SRF617

author_avatar
NASDAQ Market News

Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk

Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people ...

author_avatar
NASDAQ Market News